DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, Hui -Shan | ko |
dc.contributor.author | Wong, Nicole M. | ko |
dc.contributor.author | Tague, Elliot | ko |
dc.contributor.author | Ngo, John T. | ko |
dc.contributor.author | Khalil, Ahmad S. | ko |
dc.contributor.author | Wong, Wilson W. | ko |
dc.date.accessioned | 2023-06-07T06:00:18Z | - |
dc.date.available | 2023-06-07T06:00:18Z | - |
dc.date.created | 2023-06-07 | - |
dc.date.created | 2023-06-07 | - |
dc.date.created | 2023-06-07 | - |
dc.date.issued | 2022-11 | - |
dc.identifier.citation | CANCER CELL, v.40, no.11, pp.1294 - 1305 | - |
dc.identifier.issn | 1535-6108 | - |
dc.identifier.uri | http://hdl.handle.net/10203/307069 | - |
dc.description.abstract | Chimeric antigen receptor (CAR) T cells can revolutionize cancer medicine, However, overactivation, lack of tumor-specific surface markers, and antigen escape have hampered CAR T cell development. A multi-antigen targeting CAR system regulated by clinically approved pharmaceutical agents is needed. Here, we present VIPER CARs (versatile protease regulatable CARs), a collection of inducible ON and OFF switch CAR circuits engineered with a viral protease domain. We established their controllability using FDA-approved antiviral protease inhibitors in a xenograft tumor and a cytokine release syndrome mouse model. Furthermore, we benchmarked VIPER CARs against other drug-gated systems and demonstrated best-in-class performance. We showed their orthogonality in vivo using the ON VIPER CAR and OFF lenalidomide-CAR systems. Finally, we engineered several VIPER CAR circuits by combining various CAR technologies. Our multiplexed, drug-gated CAR circuits represent the next progression in CAR design capable of advanced logic and regulation for enhancing the safety of CAR T cell therapy. | - |
dc.language | English | - |
dc.publisher | CELL PRESS | - |
dc.title | High-performance multiplex drug-gated CAR circuits | - |
dc.type | Article | - |
dc.identifier.wosid | 000901660500009 | - |
dc.identifier.scopusid | 2-s2.0-85141500397 | - |
dc.type.rims | ART | - |
dc.citation.volume | 40 | - |
dc.citation.issue | 11 | - |
dc.citation.beginningpage | 1294 | - |
dc.citation.endingpage | 1305 | - |
dc.citation.publicationname | CANCER CELL | - |
dc.identifier.doi | 10.1016/j.ccell.2022.08.008 | - |
dc.contributor.localauthor | Li, Hui -Shan | - |
dc.contributor.nonIdAuthor | Wong, Nicole M. | - |
dc.contributor.nonIdAuthor | Tague, Elliot | - |
dc.contributor.nonIdAuthor | Ngo, John T. | - |
dc.contributor.nonIdAuthor | Khalil, Ahmad S. | - |
dc.contributor.nonIdAuthor | Wong, Wilson W. | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | RECEPTOR T-CELLS | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | RECOGNITION | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | STRATEGY | - |
dc.subject.keywordPlus | CANCER | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.